Volume 65; Issue 4

Main
Drug Development Research
Volume 65; Issue 4

Drug Development Research

Volume 65; Issue 4

1

The involvement of neuropeptides in evolution, signaling, behavioral regulation and psychopathology: focus on vasopressin

Rainer Landgraf, Florian Holsboer

Journal:

Drug Development Research

Year:

2005

Language:

english

File:

PDF, 101 KB

english, 2005

2

Can CRF1 receptor antagonists become antidepressant and/or anxiolytic agents?

David H. Overstreet, Darin J. Knapp, George R. Breese

Journal:

Drug Development Research

Year:

2005

Language:

english

File:

PDF, 176 KB

english, 2005

3

Homeostasis within the corticotropin-releasing factor system via CRF2 receptor activation: a novel approach for the treatment of anxiety

Glenn R. Valdez, Eric P. Zorrilla, George F. Koob

Journal:

Drug Development Research

Year:

2005

Language:

english

File:

PDF, 193 KB

english, 2005

4

NBI 30775 (R121919), an orally active antagonist of the corticotropin-releasing factor (CRF) type-1 receptor for the treatment of anxiety and depression

Chen Chen, Dimitri E. Grigoriadis

Journal:

Drug Development Research

Year:

2005

Language:

english

File:

PDF, 166 KB

english, 2005

5

Galanin receptors as novel drug targets for the treatment of depression and anxiety

Xiaoying Lu, Alasdair M. Barr, Tamas Bartfai

Journal:

Drug Development Research

Year:

2005

Language:

english

File:

PDF, 151 KB

english, 2005

6

Angiotensin II AT1 receptor antagonists inhibit the angiotensin-CRF-AVP axis and are potentially useful for the treatment of stress-related and mood disorders

Juan M. Saavedra, Jaroslav Pavel

Journal:

Drug Development Research

Year:

2005

Language:

english

File:

PDF, 553 KB

english, 2005

7

The brain renin–angiotensin system: a target for novel antidepressants and anxiolytics

Journal:

Drug Development Research

Year:

2005

Language:

english

File:

PDF, 121 KB

english, 2005

8

Melanin-concentrating hormone receptor 1 antagonists for the treatment of depression and anxiety

Shigeyuki Chaki, Jun-ichi Yamaguchi, Hisaharu Yamada, Kosuke Kanuma, Yoshinori Sekiguchi

Journal:

Drug Development Research

Year:

2005

Language:

english

File:

PDF, 216 KB

english, 2005

9

Small molecule melanin-concentrating hormone receptor 1 (MCH1R) antagonists as anxiolytic and antidepressive agents

Journal:

Drug Development Research

Year:

2005

Language:

english

File:

PDF, 159 KB

english, 2005

10

Neuropeptide Y receptors as therapeutic targets in anxiety and depression

Tammy J. Sajdyk

Journal:

Drug Development Research

Year:

2005

Language:

english

File:

PDF, 123 KB

english, 2005

11

Preclinical approaches to examine novel concepts of the pathophysiology of depressive disorders: lessons learned from tree shrews

Eberhard Fuchs, Boldizsár Czéh, Gabriele Flügge

Journal:

Drug Development Research

Year:

2005

Language:

english

File:

PDF, 132 KB

english, 2005

12

Potential use of neurosteroids and neuroactive steroids as modulators of symptoms of depression, anxiety, and psychotic disorders

Bernardo Dubrovsky

Journal:

Drug Development Research

Year:

2005

Language:

english

File:

PDF, 192 KB

english, 2005

13

Remission and recovery in depression treatment

Madhukar H. Trivedi, Beverly Kleiber, Tracy L. Greer

Journal:

Drug Development Research

Year:

2005

Language:

english

File:

PDF, 176 KB

english, 2005